Gout and Cardiovascular Disease: Mechanisms, Risk Estimations, and the Impact of Therapies

Mariano Andrés 1,2,3

1 Clinical Medicine Department, Miguel Hernandez University, 03550 San Juan de Alicante, Spain; mariano.andresc@umh.es
2 Rheumatology Section, Dr. Balmis General University Hospital, 03010 Alicante, Spain
3 Research Group on Rheumatic and Autoimmune Diseases, Alicante Institute for Health and Biomedical Research (ISABIAL), 03010 Alicante, Spain

Abstract: Gout is intimately associated with cardiovascular disease—especially in cases of an atherosclerosis origin, but also with others such as heart failure, atrial fibrillation, or aortic valve stenosis. Besides the common presence of vascular comorbidities in gout sufferers, the disease is—in itself—an independent cardiovascular risk factor, with disease events and mortality attributable to having this condition. This review aims to update the current knowledge regarding several grey areas of the gout–cardiovascular disease spectrum—particularly in terms of risk variations across sex or ancestries, potential monosodium urate crystal deposition in the artery tree as a pathogenic pathway, the efforts undertaken to assess risk estimations in the gout population, and recent controversies surrounding the effects of gout therapies on cardiovascular disease.

Keywords: gout; cardiovascular disease; cardiovascular risk; tophi; inflammation; hyperuricemia

1. Introduction

Gout is the monosodium urate (MSU) crystal deposition disease. The experts from the Gout, Hyperuricemia, and Crystal-Associated Disease Network (G-CAN) have defined the disease as being present when MSU crystal deposition is accompanied by clinical manifestations such as flares, persistent arthritis, and/or tophi [1]. However, the transition from asymptomatic hyperuricemia to gout may be sometimes blurred—especially when MSU crystals are already formed [2]. The disease is clinically characterized by recurrent, self-limited episodes of joint inflammation, and in long-duration cases with insufficient or absent treatment, subcutaneous tophi and/or chronic arthritis. Moreover, patients with gout suffer from disabilities and an impaired quality of life, with higher scores (worse status) on several scales such as the Gout Assessment Questionnaire, Health Assessment Questionnaire–Disease Index, or the Short-Form 36 compared to controls—even during flare-free periods [3]. Hospitalizations due to gout have almost doubled in the last decades [4–6] and, more importantly, mortality rates in patients with gout greatly surpass those of the general population (all-cause standardized mortality ratio of 2.21) [7].

There is a close relationship between gout and cardiovascular diseases (CVD). Patients with gout present myriad comorbidities, in which cardiovascular risk factors such as hypertension, dyslipidemia, a smoking habit, obesity, diabetes mellitus, and chronic kidney disease [8–13] play a relevant role. Vascular diseases account for more than half of deaths among gout sufferers; indeed, for up to six points higher than the cardiovascular mortality of the general population, according to European data [7,14,15]. Interestingly, there is a bidirectional effect between gout and CVD; after a gout flare, the risk of cardiovascular events increases—especially in the short-term [16]. In addition, having gout worsens a patient’s prognosis following a cardiovascular event [17,18] or success rates following coronary revascularization [19]. Furthermore, gout flares are common during hospitalizations due to CVD [20]. Data also exists for other types of CVD not purely related to atherosclerosis,
such as atrial fibrillation [21–24], heart failure [25,26], and aortic valve stenosis [27]. Pooled data from DATA-HF and DELIVER trials on dapagliflozin recently reported worse heart failure outcomes in the gout population [28].

Cardiovascular risk factors do not fully explain the increased incidence of CVD, as there remains a residual risk even after adjusting for those covariates. Accordingly, gout must be considered an independent cardiovascular risk factor—indicating that patients with gout have a heightened cardiovascular risk merely from suffering the condition. The risk associated with gout has been demonstrated for all forms of atherosclerotic CVD and their derived mortality rates [15,29–44], as shown in Table 1. In this sense, aggregate data show that the risk of gout patients dying due to CVD is 1.29-fold higher, and up to 1.42-fold higher for coronary disease-related deaths [36]. Compared to diabetes, gout shows an equivalent risk of leading to stroke—though less so for cases of myocardial infarction [45] or limb amputation [46]. Cardiovascular risk is heightened in cases of larger MSU crystal burden, such as patients with subcutaneous tophi [7,14,47,48] or with a large crystal load as assessed by ultrasound [49] or dual-energy computed tomography (DECT) [50]. Interestingly, the presence of a sonographic power-Doppler signal in tandem with crystal deposits—a surrogate marker of inflammation—was also associated with carotid atherosclerosis [49].

Table 1. Published studies linking gout and the different forms of atherosclerotic cardiovascular disease.

<table>
<thead>
<tr>
<th>Paper</th>
<th>Population</th>
<th>Type of Cardiovascular Disease</th>
<th>Gout Population, Compared to Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choi, 2007 [29]</td>
<td>Health Professionals Follow-up Cohort</td>
<td>Cardiovascular mortality</td>
<td>RR 1.35 (1.19–1.55)</td>
</tr>
<tr>
<td>Kuo, 2010 [30]</td>
<td>Chang Gung Memorial Hospital, Taiwan</td>
<td>Cardiovascular mortality</td>
<td>HR 1.97 (1.08–3.59)</td>
</tr>
<tr>
<td>Kuo, 2011 [31]</td>
<td>National Death Registry of Taiwan</td>
<td>Cardiovascular mortality</td>
<td>SMR 1.58 (1.39–1.78) in men</td>
</tr>
<tr>
<td>Stack, 2013 [32]</td>
<td>NHANES-III</td>
<td>Cardiovascular mortality</td>
<td>HR 1.46 (1.07–2.00)</td>
</tr>
<tr>
<td>Dehlin, 2022 [15]</td>
<td>Western Sweden</td>
<td>Cardiovascular mortality</td>
<td>HR 1.17 (1.12–1.23)</td>
</tr>
<tr>
<td>Abbott, 1988 [33]</td>
<td>Framingham Study</td>
<td>Coronary heart disease</td>
<td>RR 1.6 (1.1–2.5)</td>
</tr>
<tr>
<td>Krishnan, 2006 [34]</td>
<td>Multiple Risk Factor Intervention Trial</td>
<td>Coronary heart disease</td>
<td>OR 1.26 (1.14–1.40)</td>
</tr>
<tr>
<td>Seminog, 2013 [35]</td>
<td>UK National Linked Dataset of Admissions and Deaths</td>
<td>Coronary heart disease</td>
<td>RR 1.82 (1.78–1.85) in England data</td>
</tr>
<tr>
<td>Clarson, 2015 [36]</td>
<td>UK Clinical Practice Research Datalink</td>
<td>Coronary heart disease</td>
<td>HR 1.08 (1.01–1.15) in men</td>
</tr>
<tr>
<td>Huang, 2021 [38]</td>
<td>Taiwan National Health Insurance database</td>
<td>Coronary heart disease</td>
<td>HR 1.25 (1.12–1.39) in women</td>
</tr>
<tr>
<td>Singh, 2018 [37]</td>
<td>US Medicare dataset</td>
<td>Coronary heart disease (older adults)</td>
<td>HR 1.79 (1.68–1.90)</td>
</tr>
<tr>
<td>De Vera, 2010 [39]</td>
<td>Former Medical Students Cohort</td>
<td>Coronary heart disease (women)</td>
<td>RR 1.39 (1.20–1.61) in females</td>
</tr>
<tr>
<td>Kuo, 2013 [40]</td>
<td>Taiwan National Health Insurance Database</td>
<td>Coronary heart disease (Young patients with no CVDRF)</td>
<td>RR 1.11 (0.99–1.23) in males</td>
</tr>
<tr>
<td>Haddadin, 2021 [41]</td>
<td>US National Inpatient Sample</td>
<td>Stroke</td>
<td>OR 1.10 (1.01–1.11) in an AF population</td>
</tr>
<tr>
<td>Clarson, 2015 [36]</td>
<td>UK Clinical Practice Research Datalink</td>
<td>Peripheral artery disease</td>
<td>HR 1.18 (1.01–1.38) in men</td>
</tr>
<tr>
<td>Schlesinger, 2015 [42]</td>
<td>Rutgers-Robert Wood Johnson Rheumatology Department</td>
<td>Erectile dysfunction</td>
<td>OR 2.94 (1.41–6.06)</td>
</tr>
</tbody>
</table>
Despite the established evidence, there are still numerous uncertainties and unsolved questions regarding the relationship between gout and CVD that merit discussion. Relevant topics such as gender and ethnic variations in risk impact, the mechanism underlying accelerated atherosclerosis, how cardiovascular risk may be estimated in gout patients, and whether gout therapies positively or negatively influence CVD all fall within the scope of this review.

2. Are There Differences According to Sex or Ancestry?

Gout mostly occurs in men, with some women developing gout after menopause—although in lower numbers than men. Several studies and our clinical practice experience have identified different comorbidity profiles when comparing men and women with gout [12,51,52]. Women suffering from gout are almost ten years older and more commonly present with heart failure, renal disease, hypertension, and/or obesity. Being older and having a greater use of diuretics partially explain these different comorbidity profiles—some of which are present at the time of the gout diagnosis, suggesting they may play a role in the disease’s pathogenesis. Only a few papers on gout-attributable CVD have included a sex comparison. Clarson and colleagues [36], using data from the UK Clinical Practice Research Datalink, noted higher risk ratios in women for any vascular disease, angina, stroke, and/or peripheral vascular disease, but not for myocardial infarction. Seminog and Goldacre observed a mildly increased risk of myocardial infarction in women, but found no differences with stroke [35]. In addition, De Vera et al. also found that women had a significantly higher risk of myocardial infarction—though only for non-fatal cases [39]. Conversely, Singh and Cleveland found a lower risk of myocardial infarction in older women compared to men treated via the Medicare system [37]. Some studies reported similar mortality rates in both sexes [31,32]. This is a complex scenario in which evaluating how gout impacts cardiovascular risk is challenging—especially when women might be underrepresented in the samples, as gout is less prevalent in this population. Further research primarily focused on sex-based differences in cardiovascular risk is needed.

Most studies cited in the previous section involved datasets of mostly white populations. Indeed, whether gout may differently impact groups of other ancestries has received scant critical attention to date. However, this is a crucial issue, as non-white populations are at risk of racial blindness in gout screening. African Americans in the US are less likely to be diagnosed with gout [53], despite a higher prevalence of metabolic syndrome, hypertension, and renal disease [54]. In New Zealand, being of Māori or Pacific Islander ethnicity, who are known to have higher and more severe rates of gout, were independent predictors of all-cause mortality in a gout cohort—although not for cardiovascular-related mortality [48]; however, these populations are at higher risk of CVD compared to whites, according to one recent report [35]. Furthermore, as shown in Mexican populations [56], those with tophaceous disease are usually found in low-income classes and more often use glucocorticoids (cheaper drugs), which likely worsens their cardiovascular risk.

### Table 1. Cont.

<table>
<thead>
<tr>
<th>Paper</th>
<th>Population</th>
<th>Type of Cardiovascular Disease</th>
<th>Gout Population, Compared to Controls a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chen, 2015 [43]</td>
<td>Taiwan National Health Insurance Database</td>
<td>Erectile dysfunction</td>
<td>HR 1.40 (1.11–1.77) in those without comorbidities HR 2.04 (1.63–2.57) in those with comorbidities</td>
</tr>
<tr>
<td>Abdul Sultan, 2017 [44]</td>
<td>UK Clinical Practice Research Datalink</td>
<td>Erectile dysfunction</td>
<td>HR 1.31 (1.24–1.40)</td>
</tr>
</tbody>
</table>

* a Risk estimators adjusted for several covariates (varying across the different studies). In parentheses, 95% confidence intervals are shown. AF: atrial fibrillation; CVDRF: cardiovascular disease risk factors; HR: hazard ratio; OR: odds ratio; RR: risk ratio; SMR: standardized mortality ratio.
3. How MSU Crystals May Foster Cardiovascular Risk?

Aside from comorbidities, two major contributors likely underlie this heightened cardiovascular risk [57]: hyperuricemic states and the inflammation driven by MSU crystal deposition. A pro-oxidative state has been reported in hyperuricemia, as uric acid formation by the enzyme xanthine oxidase (or xanthine dehydrogenase) leads to pro-oxidative species production, such as the peroxide anion. A higher presence of small, oxidized, low-density lipoprotein (LDL)-cholesterol particles has been described in hyperuricemic subjects; these particles are capable of penetrating the atheroma plaque and aggravating atherosclerosis. Moreover, murine models [58] and clinical data [59] confirm that hyperuricemia can lead to the onset of arterial hypertension—at least during the younger stages of life, probably through endothelial dysfunction. However, inflammation is the principal suspect linking gout and CVD, mirroring other inflammatory diseases [60–62]. MSU crystals can activate the NLRP3 inflammasome cascade, which in turn leads to the synthesis and production of interleukin (IL)-1beta and IL-18, the main cytokines in crystal-driven inflammation [63]. Interestingly, cholesterol crystals share the same inflammatory pathway in atheroma plaques [64]. The intensity of inflammation markedly fluctuates in patients with gout [65]. Beyond peaks of acute, clinical inflammation (gout flares), there can be persistent, subclinical inflammation during the inter-critical stage [66] that increases with greater crystal loads [67,68]—but this tends to decrease during urate-lowering therapies [69] or via the use of colchicine [70]. Apart from MSU crystal deposits, hyperuricemia itself plays a role in inflammation as well. Soluble urate can enhance the inflammatory response through multiple mechanisms in innate immune cells [71], while increased NLRP3 inflammasome expression has been noted in atheroma plaques from hyperuricemic patients [72].

An interesting debate concerns whether MSU crystals are able to form and deposit at atheroma plaques, where they could induce local inflammation and hypothetically worsen atherosclerosis. Xanthine oxidase activity is known to occur at plaques, which contributes to locally increased levels of uric acid—although some pathology papers have reported the presence of uric acid crystals based on birefringence and immunostaining [73,74]. DECT scans have detected color-coded MSU deposits in the vascular tree, along with calcified plaques [75–77]. Of note, subsequent scans during urate-lowering therapies have found no reduction in vascular deposits (the deposits have even grown), while musculoskeletal deposits do, in fact, diminish [77]. Such vascular deposits could not be later replicated using cadaveric donors who had suffered from gout [78]. Our group found the scattered presence of MSU-looking crystals in peripheral artery specimens using compensated polarized microscopy—although no relationship with patient serum urate levels was established [72]. This suggests that, should these MSU crystals exist in atheroma plaques, their presence might result from the local synthesis that follows increased cell necrosis and turnover, rather than deriving from hyperuricemia. The presence of MSU crystals at atheroma plaques warrants definitive confirmation—possibly using crystallographic techniques with a specificity high enough to identify MSU.

4. How Can We Gauge Cardiovascular Risk in Patients with Gout?

As cardiovascular risk levels vary across individuals, predicting the specific risk for any given patient with gout is vital to tailoring his/her clinical management—both from a cardiovascular perspective and in terms of gout. This aspect is especially relevant for people without established CVD. To this end, some risk assessment tools have been developed to simultaneously evaluate individual cardiovascular risk factors and assess the risk of developing CVD, including fatal events. Some tools largely used in primary care include the Framingham Heart Study (FHS) [79] and the Systematic Coronary Risk Evaluation (SCORE) [80], which has been recently updated as SCORE2 [81]. However, no validation studies have been performed in patients with gout. Data from other inflammatory diseases such as rheumatoid arthritis have pointed to risk underestimation [82], which has led to the development of specific risk calculators; for example, the ERS-RA [83]. Our group evaluated the performance of FHS and SCORE in detecting the presence of subclinical...
carotid atherosclerosis [13]. Both tools were only moderately accurate, with areas under the curve of 0.707 and 0.705, respectively. Both lacked sufficient sensitivity (22.5% and 49.0%) despite good specificity results (89.3% and 80.4%), suggesting the possibility that high-risk cardiovascular subjects can go undetected. Gamala and colleagues later reported that a substantial risk reclassification of gout patients can be achieved if they are classified as having inflammatory arthritis as per the Dutch-adapted SCORE [84]; however, longitudinal data is needed to validate this prediction.

The screening for subclinical atherosclerosis using ultrasound is simple, accessible, and reliable—especially for carotid arteries (Figure 1), which carry prognostic consequences. The European cardiovascular guidelines recommend that the identification of subclinical atherosclerosis should prompt the physician to classify the patient as being in the highest cardiovascular risk category [85], since this factor independently predicts both coronary and cerebrovascular events [86,87]. On the other hand, the guidelines caution against making risk estimations based on intima-media thickness measurements. The reported prevalence of carotid atheroma plaques in patients with gout ranges from 29.1% to 59.2% [13,49,88–91]—percentages that vary depending on several factors (such as patient demographics and/or disease duration). In any case, the percentage is likely higher than in people without gout. Our group demonstrated that a cardiovascular screening strategy incorporating risk assessment tools and carotid ultrasound is capable of reclassifying the risk of more than half of new gout patients seen in rheumatology clinics, with two-thirds of them ultimately meeting the very-high risk level threshold [13].

![Figure 1. Ultrasound of right carotid artery, longitudinal view, in a patient with gout who had a moderate cardiovascular risk as assessed by scores. The exam revealed two atheroma plaques, mildly calcified, of 1.5 mm (1) and 2.1 mm (2) thickness. According to current European guidelines, this patient should be classified as having a very high cardiovascular risk and managed accordingly.](image-url)
However, it is crucial to bear in mind that both risk assessment tools and carotid ultrasound are not applicable to high-risk subjects, as these individuals are already suffering from CVD, complicated diabetes mellitus, and/or advanced renal disease. Patients with tophaceous gout may be tentatively included in this group. Despite conflicting evidence surrounding its possible association with subclinical atherosclerosis [13,90,91], subcutaneous tophi are major predictors of subsequent all-cause and cardiovascular mortality—as previously mentioned. Standard guidelines offer no formal advice in this regard, and individual clinicians should perhaps consider whether, based on the cumulative data, these patients might benefit from preventive strategies for high-risk situations. These could include high-intensity statins or rigorous targeting of LDL-cholesterol or blood pressure [85], along with lower serum urate targets [92,93].

5. Can Gout Management Ameliorate Cardiovascular Risk?

As previously discussed, MSU crystal deposition likely plays a leading role in gout-driven CVD via persistent, subclinical inflammation and perhaps arterial accumulation. MSU crystal deposition can be reversed through the normalization of serum urate levels [94]; in fact, urate levels and previous gout duration are determinants for achieving a complete removal of such deposits [93,95]. Accordingly, MSU crystal dissolution by ULT should lower cardiovascular risk—although to date this outcome remains uncertain. The question of efficacy would need to be addressed through a clinical trial, but enrolling a group of untreated gout participants serving as controls would be unethical. Subsequently, research should focus on large datasets and population-based studies. To date, conflicting results have been published, with some studies showing the very real benefits of ULT in terms of cardiovascular risk [96–98], while others reported inconclusive findings [32,99–101] or a null effect [102–104]. These discrepancies can be explained, at least partially, by insufficient gout management in clinics—where many patients are not prescribed ULT, are insufficiently dosed, or whose serum urate levels are not properly monitored for dosing adjustments or adherence verification. Poor gout care has been repeatedly reported both for general practitioners [105,106] and rheumatologists [107,108], even in patients with established CVD [109]. Thus, derived data may not be sufficiently robust to draw any conclusions. One example of solid data is that published by Perez Ruiz and colleagues [110]; in their survival analysis of an inception gout cohort, the authors found that not achieving the urate target (below 6 mg/dL) was independently associated with a 2.39-fold higher risk of subsequent all-cause mortality, and a 2.37-fold higher risk of cardiovascular mortality. While more research using robust data is needed, their findings reinforce the importance of treating gout with a defined target [111], as well as for cardiovascular purposes.

In addition to serum urate control, anti-inflammatory therapies themselves may potentially prevent CVD in patients with gout. Atherosclerosis is a chronic inflammatory disease resulting from lipid accumulation at the arterial wall following endothelial dysfunction, the infiltration of macrophages and smooth muscle cells, and NLRP3 inflammasome activation by cholesterol crystals—leading to IL-1β and IL-18-mediated inflammation [112]. This inflammatory process aggravates atheroma plaques—thereby favoring its growth and eventual rupture. The innate immune system plays a key role in this process. In contrast, interfering with adaptive immunity has proven unsuccessful [113]. In this scenario, two gouty anti-inflammatory agents—colchicine [114–116] and IL-1β blocker canakinumab [117]—were shown to be effective at preventing CVD in trials. Compared to a placebo in patients with established CVD under standard preventive care, both agents significantly reduced the recurrence of major cardiovascular events—highlighting the beneficial impact anti-inflammatory approaches can have when attempting to lower the so-called residual inflammatory risk [118]. As gout was underrepresented, or was a reason for exclusion in these trials, findings should not be extrapolated to gouty patients. However, published observational data suggest that colchicine confers some cardiovascular benefits in this population [119–122]. Indeed, the data suggests that extended regimens
of colchicine, beyond the common recommendation of 6 months [92], may be suitable for individuals at very high cardiovascular risk (based on our data, this would correspond to two-thirds of the patients treated at rheumatology clinics [13]). Nevertheless, evidence from randomized trials would be very welcome to confirm the effectiveness of this strategy. No cardiovascular data on canakinumab or other IL-1β blockers in gout patients is currently available.

6. Do the Cardiovascular Profiles of Xanthine Oxidase Inhibitors Differ?

In the pivotal APEX and FACT trials [123,124], participants receiving febuxostat showed a rate of 1.3 cardiovascular events per 100 patient-years—numerically higher than those administered allopurinol (0.3 events per 100 patient-years). Specifically, in APEX, the percentage of CVD was 2%, 2%, and <1% in those receiving febuxostat 80 mg/day, 120 mg/day, and 240 mg/day, respectively, while the percentage in those treated with allopurinol was <1% [123]. Already having a CVD (either coronary heart disease or heart failure) was the main predictor of vascular events during therapy. Though the later CONFIRMS trials showed no differences in terms of CVD—occurring in 5% of those treated with febuxostat 80 mg/day, 5% with febuxostat 120 mg/day, or 6% with allopurinol 300 mg/day [125]—initial data led regulatory agencies to require cardiovascular safety analyses through randomized trials conducted by the manufacturers.

The first available trial was the CARES study, which was carried out in the United States [126]. CARES was a non-inferiority safety trial involving patients with gout and established CVD (a minor percentage had conditions regarded as very-high risk, such as complicated diabetes). These patients were randomized to receive allopurinol 300 mg/day or febuxostat 40–80 mg/day. After enrolling and analyzing over 6000 participants, no differences in major cardiovascular events were noted. However, rates of all-cause mortality (not included in the primary composite outcome) and CVD mortality were significantly higher in the febuxostat group. These findings led the Food and Drug Administration (FDA) to issue a black warning to avoid the use of febuxostat in patients with high cardiovascular risk. However, the trial had an excessive drop-out rate (56.6%) and most events occurred during the drug-free stage [127], which constitutes a major limitation for a non-inferiority safety trial. As febuxostat achieved lower serum urate levels than allopurinol, a rebound peak after drug discontinuation might explain the reported deaths—although the evidence does not convincingly support such a conclusion [128]. Moreover, an imbalanced use of NSAIDs or low-dose aspirin and the absence of a non-treated group complicate the interpretation of the CARES trial results.

The European safety trial, known as the FAST study, was published in 2020 [129]. This trial had the same aim but utilized a different methodology. The authors enrolled gout patients aged 60 years or older on a stable dose of allopurinol (6 years was the average) and who presented with an additional cardiovascular risk factor. In all, while 33.4% had established CVD, recent cases or those with severe congestive heart failure were excluded. Allopurinol dosing was adjusted to a serum urate below 6 mg/dL, and participants were later randomized in order to continue treatment with adjusted allopurinol, or they received febuxostat 80 mg/day (increased later to 120 mg/day if the urate target was not met), with no blinding. Around 5700 participants were enrolled, with a good rate of study completion (86.2%) and with few discontinuing their visits (5.8%, excluding deaths). The authors found no differences in the occurrence rates of CVD during follow-up, with similar results for CVD-related deaths, and even a lower rate of all-cause mortality was noted in those treated with febuxostat.

The results of the FAST trial were reassuring and suggested that xanthine oxidase inhibitors had a similar cardiovascular profile for patients with gout. In addition, a recent head-to-head efficacy trial comparing febuxostat versus allopurinol, with doses adjusted to serum urate levels [130], found no differences in cardiovascular events during the study. Several recent observational studies have addressed this topic, with conflicting results [131–134]; these studies are limited by the risk of indication bias, as well as difficult
confounder adjustments intended to avoid the effect of residuals. Most likely, aside from the controversy surrounding the cardiovascular consequences of gout therapies, the benefits they offer—especially in a CVD setting—should confirm their superiority.

7. What Is My Cardiovascular Approach in Clinical Practice?

A systematic cardiovascular assessment of any gout patient is essential from the initial visit. This assessment should include an interview to assess the patient’s history of CVD, including non-atherosclerotic disorders such as atrial fibrillation or heart valve lesions, as well as a physical exam to record blood pressure, body mass index, and subcutaneous tophi. Laboratory tests measuring fasting lipids and glucose, glycated haemoglobin, and the urinary albumin/creatinine ratio (a marker of target organ damage that can also indicate gouty renal disease [135]), is worthwhile. Based on the findings, cardiovascular risk should be estimated according to the patient’s CVD background, renal function, and risk assessment tools (FHS or SCORE). Patients may be classified as being at low, moderate, high, or very high risk; those at the moderate level are the best candidates for carotid ultrasound. If an atheroma plaque is found, intensive statin therapy should be undertaken, with the goal of lowering LDL-cholesterol levels below 70 mg/dL. It is important to liaise with allied specialists (e.g., cardiologists, nephrologists, endocrinologists, etc.) and any attendant nursing specialties in cases involving troublesome or difficult-to-manage comorbidities.

The cardiovascular care of any patient with gout should also include disease management with the goal of enhancing MSU crystal dissolution, reducing inflammation, and controlling hyperuricemia. Beginning urate-lowering agents even after the first flare should be recommended for all patients [92], with a urate target goal of around 4 mg/dL in most cases—although in severe cases (tophaceous disease, persistent arthritis, severe impairment, etc.) this should be set even lower. To enhance serum urate reduction, certain comorbidity therapies—such as losartan, calcium blockers, fenofibrate, or sodium–glucose transporter-2 inhibitors—can be of help. Regarding loop diuretics and thiazides, in our experience they do not impede urate target goals [136]. Thus, one option would be to halt their use if deemed non-essential (e.g., arterial hypertension controlled with one or two drugs). Here, the strategy would involve long-term maintenance of urate levels in order to prevent new crystal formations. Preventive low-dose colchicine for longer than recommended periods (6 months) may be a good option for patients with established CVD or for those who are carrying a heavy crystal burden.

8. Pending Questions and Conclusions

Notable advances have occurred in the last decade that have bettered our understanding of the relationship between gout and CVD. Rather than being a mere bystander, gout is an independent cardiovascular risk factor associated with crystal-driven inflammation and hyperuricemia. Limited data suggest that gout has a similar cardiovascular impact on both men and women. Some disease features indicating a larger crystal burden, such as subcutaneous tophi, should be taken as markers of high risk. Ultrasound and DECT have helped establish a link between crystal deposits and atherosclerotic disease, and the former may prove useful as an estimator in clinical practice. The goal of crystal dissolution should be driven by urate-lowering therapies, which may also provide cardiovascular benefits—despite the conflicting data. Anti-inflammatory therapies could also help in this setting, mirroring data from patients with CVD. However, there are still some grey areas (Table 2) that must be properly addressed with further research. As CVD remains the primary cause of mortality in those with gout, these patients and their families would be very grateful indeed.
Table 2. Pending and unresolved questions, as well as recommended research agendas for gout and cardiovascular disease.

<table>
<thead>
<tr>
<th>Area</th>
<th>Issues and Necessities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathogenesis</td>
<td>To prove MSU crystal deposition occurs at the atheroma plaque, with deleterious effects.</td>
</tr>
<tr>
<td></td>
<td>To define the mechanisms linking crystal-driven inflammation and the aggravation of atherosclerosis.</td>
</tr>
<tr>
<td></td>
<td>To determine when high cardiovascular risk begins—with the first flare or with the first deposited crystal (asymptomatic).</td>
</tr>
<tr>
<td></td>
<td>To discriminate whether a gender impact of gout exists in terms of the cardiovascular profile.</td>
</tr>
<tr>
<td></td>
<td>To foster knowledge of the cardiovascular impact of gout on non-White populations.</td>
</tr>
<tr>
<td>Assessment</td>
<td>To develop accurate risk prediction tools for gout—likely including disease-specific characteristics such as serum urate or subcutaneous tophi.</td>
</tr>
<tr>
<td></td>
<td>To perform studies on the cost-effectiveness of introducing carotid ultrasound for reclassifying cardiovascular risk in gout patients.</td>
</tr>
<tr>
<td></td>
<td>To introduce other forms of subclinical atherosclerosis screening, such as coronary calcium scores or computed tomography angiography.</td>
</tr>
<tr>
<td></td>
<td>To describe the evolution of subclinical atherosclerosis under urate-lowering therapies.</td>
</tr>
<tr>
<td>Management</td>
<td>To evaluate the cardiovascular outcomes of treat-to-target approaches in patients with gout.</td>
</tr>
<tr>
<td></td>
<td>To delineate the benefits of primary and secondary cardiovascular prevention in patients with gout.</td>
</tr>
<tr>
<td></td>
<td>To study the cardiovascular profile of xanthine oxidase inhibitors compared to other agents such as uricosurics or uricases.</td>
</tr>
<tr>
<td></td>
<td>To determine the cardiovascular benefits of colchicine in gout patients and the optimal length of therapy.</td>
</tr>
<tr>
<td></td>
<td>To assess the cardiovascular benefits of SGLT2i for patients with gout—even in the absence of diabetes or heart failure.</td>
</tr>
</tbody>
</table>

MSU: monosodium urate; SGLT2i: sodium-glucose cotransporter 2 inhibitors.

**Funding:** The author’s work is funded by the Carlos III Health Institute (Acción Estratégica en Salud 2021, ref. PI21/00544; Contratos para Intensificación en el SNS 2022, ref. INT22/00023), co-funded by the European Union. The author would like to thank the Spanish Foundation of Rheumatology for providing medical writing/editorial assistance during the preparation of the manuscript (ref. FERBT2023).

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The author declares speaking fees from Menarini and an ongoing research grant from Grunenthal.

**References**


15. Dehlin, M.; Sandström, T.Z.; Jacobsson, L.T. Incident Gout: Risk of Death and Cause-Specific Mortality in Western Sweden: A Prospective, Controlled Inception Cohort Study. Front. Med. 2022, 9, 802856. [CrossRef]

16. Cipolletta, E.; Tata, L.J.; Nakafuro, G.; Avery, A.J.; Mamas, M.A.; Abhishek, A. Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout. JAMA 2022, 328, 440–450. [CrossRef]


25. Krishnan, E. Gout and the Risk for Incident Heart Failure and Systolic Dysfunction. BMJ Open 2012, 2, e000282. [CrossRef]


47. Calabuig, I.; Martinez-Sanchis, A.; Andris, M. Sonographic Tophi and Inflammation Are Associated With Carotid Atheroma Plaques in Gout. *Front. Med.* 2021, 8, 799984. [CrossRef]


50. Vázquez-Mellado, J.; Cruz, J.; Guzmán, S.; Casassola-Vargas, J.; Lino, L.; Burgos-Vargas, R. Severe Tophaceous Gout: Comparison of Rates of Lower Extremity Amputation in Patients With and Without Gout in the US Department of Veterans Affairs Health System. *JAMA Netw. Open* 2022, 5, e2142347. [CrossRef]


127. Ghang, B.-Z.; Lee, J.S.; Choi, J.; Kim, J.; Yoo, B. Increased Risk of Cardiovascular Events and Death in the Initial Phase after Discontinuation of Febuxostat: Another Story of the CARES Trial. *RMD Open* 2022, 8, e001944. [CrossRef]


**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.